You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Baxter
McKesson
Moodys
Dow

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

TOSYMRA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Tosymra, and what generic alternatives are available?

Tosymra is a drug marketed by Upsher Smith Labs and is included in one NDA. There are seven patents protecting this drug.

This drug has sixty-one patent family members in nineteen countries.

The generic ingredient in TOSYMRA is sumatriptan. There are twenty-four drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tosymra

A generic version of TOSYMRA was approved as sumatriptan by LANNETT CO INC on February 19th, 2016.

  Get Started for $10

Summary for TOSYMRA
International Patents:61
US Patents:7
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for TOSYMRA
What excipients (inactive ingredients) are in TOSYMRA?TOSYMRA excipients list
DailyMed Link:TOSYMRA at DailyMed
Drug patent expirations by year for TOSYMRA
Drug Prices for TOSYMRA

See drug prices for TOSYMRA

US Patents and Regulatory Information for TOSYMRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TOSYMRA

Country Patent Number Estimated Expiration
Brazil PI0923403   Get Started for $10
Japan 2012513412   Get Started for $10
World Intellectual Property Organization (WIPO) 2006025882   Get Started for $10
United Kingdom 202012086   Get Started for $10
Russian Federation 2018107419   Get Started for $10
Russian Federation 2011130526   Get Started for $10
European Patent Office 1789075   Get Started for $10
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKesson
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.